

# Yasheng Zhu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10110392/publications.pdf>

Version: 2024-02-01

18  
papers

1,789  
citations

516710

16  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

3352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclin Dâ€“CDK4 kinase destabilizes PD-L1 via cullin 3â€“SPOP to control cancer immune surveillance. <i>Nature</i> , 2018, 553, 91-95.	27.8	660
2	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKTâ€“mTORC1 activation. <i>Nature Medicine</i> , 2017, 23, 1055-1062.	30.7	225
3	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. <i>Oncotarget</i> , 2014, 5, 11091-11102.	1.8	160
4	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
5	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Molecular Cell</i> , 2015, 59, 904-916.	9.7	129
6	Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. <i>Molecular Cancer</i> , 2019, 18, 170.	19.2	79
7	A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression. <i>Cancer Letters</i> , 2016, 374, 62-74.	7.2	64
8	SPOP E3â€“Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. <i>Cell Reports</i> , 2015, 13, 1183-1193.	6.4	55
9	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. <i>Developmental Cell</i> , 2019, 48, 329-344.e5.	7.0	53
10	SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. <i>Molecular Cancer</i> , 2021, 20, 100.	19.2	36
11	Novel Long Non-coding RNA IncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. <i>Molecular Therapy</i> , 2020, 28, 2473-2487.	8.2	33
12	The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. <i>International Journal of Cancer</i> , 2020, 146, 475-486.	5.1	27
13	Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 384.e9-384.e20.	1.6	25
14	Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP?. <i>Disease Markers</i> , 2019, 2019, 1-10.	1.3	23
15	Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. <i>Oncotarget</i> , 2015, 6, 40611-40621.	1.8	17
16	OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. <i>Communications Biology</i> , 2022, 5, 182.	4.4	10
17	Heterogeneity of PTEN and PPARâ€“Î³ in cancer and their prognostic application to bladder cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3177-3183.	1.8	8
18	ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression. <i>Cell Death and Differentiation</i> , 2022, 29, 1611-1624.	11.2	5